MYC and ovarian cancer: For example, baicalein is known to inhibit the expression of VEGF, HIF-1α, c-Myc or NF-κB in ovarian cancer cells, thereby inhibiting the metastatic potential of ovarian cancer cells, while the effect on normal cells is generally less [15,26].